Functional Dyspepsia
Conditions
Brief summary
Functional dyspepsia (FD) is a common functional gastrointestinal disorder characterized by upper abdominal discomfort/pain and/or symptoms of meal-related fullness/satiety. There is currently no definitive therapy that is beneficial for all FD patients. Accumulating evidence suggests efficacy of tricyclic antidepressants (TCAs) in FD. However, no firm conclusion can be drawn currently due to the relatively small amount of studies and large heterogeneity between studies. In addition, TCAs are often associated with side effects, which occur early after initiation of therapy preceding the therapeutic effect and often result in discontinuation of the therapy. These side effects are related to drug metabolism, which depend on polymorphisms of the cytochrome P (CYP) enzyme system. It is therefore hypothesized that pre-treatment assessment of CYP genotype and subsequent exclusion of abnormal metabolizers limits the occurrence of side-effects and as such improves compliance and efficacy.
Interventions
DRUGNortriptyline
Nortriptyline escalating dose regimen: Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg
DRUGPlacebo
Placebo
Sponsors
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-65 years; * A diagnosis of FD according to the Rome IV criteria; * Predicted CYP2D6 extensive metabolizer phenotype on the basis of CYP genotyping * Insufficient effect of first line treatment with proton pump inhibitors (twice daily) or prokinetics; * In the presence of alarm symptoms, patients are required to have undergone an upper gastrointestinal endoscopy (without evidence of organic disease), and have tested negative for Helicobacter pylori 2 years prior to inclusion; * Women in their fertile age (\<55 years old) must use contraception or be postmenopausal for at least two years.
Exclusion criteria
* Predicted CYP2D6 poor, intermediate or ultrarapid metabolizer phenotype on the basis of CYP genotyping * Evidence of current anxiety and/or depression disorder as defined by a score ≥ 10 on the GAD-7 and/or PHQ-9 questionnaire; * Current use or any previous use of psychotropic medication in the last 3 months prior to inclusion; * Inability to discontinue prokinetics, NSAIDs or opioids; * Using drugs of abuse; * Using more than 2 or 3 units of alcohol per day (females and males respectively) * Previous major abdominal surgery or radiotherapy interfering with gastrointestinal function: 1. Uncomplicated appendectomy, cholecystectomy and hysterectomy allowed unless within the past 6 months; 2. Other surgery upon judgment of the principle investigator; * History of gastric ulcer; * History of liver disease, cholangitis, achlorhydria, gallstones or other diseases of the gallbladder/biliary system; * History of epilepsy * History of glaucoma * Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptom response | 12 weeks | Response to therapy, as defined by a 30% reduction from baseline (i.e. the run-in period) in the weekly average of daily symptom scores, during at least 50% of weeks 3-12 of treatment. Symptoms will be assessed daily using a digital diary (mobile phone application). Recorded symptoms include the five core symptoms of FD: epigastric pain, epigastric burning, postprandial fullness, early satiety and upper abdominal bloating. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| General quality of life | 12 weeks, 3 & 6 months | Assessed with the use of the Euro-Qol-5D (EQ-5D; change from baseline). |
| Dyspepsia-specific quality of life | 12 weeks, 3 & 6 months | Dyspepsia-specific quality of life, assessed with the use of the Nepean Dyspepsia Index (NDI; change from baseline). |
| Cost-utility | 12 weeks, 3 & 6 months | Cost-utility, as determined by calculations incorporating total treatment costs and changes in EQ-5D-5L (QALYs gained), and results from the Medical Consumption Questionnaire (MCQ) and Productivity Cost Questionnaire (PCQ) \[savings from reduced medical resource use and increased work productivity respectively\]. |
| Use of rescue medication. | 12 weeks | As reported via digital diary (mobile phone application) |
| Adequate relief | 12 weeks | Self-reported adequate relief. Adequate relief is defined as a 'yes' response in at least 50% of weeks 3-12 of the treatment. Reported via digital diary (mobile phone application) |
| Responder rates following discontinuation | 6 months | Responder rates following discontinuation of treatment at 6 months follow-up, as defined by a Yes to the query regarding adequate relief from baseline symptoms. |
| Negative mood - anxiety | 12 weeks, 3 & 6 months | Assessed with the use of the Generalized Anxiety Disorder-7 (GAD-7; change from baseline) |
| Negative mood - depression | 12 weeks, 3 & 6 months | Assessed with the use of the Patient Health Questionnaire-9 (PHQ-9; change from baseline) |
| Number and severity of side effects. | 12 weeks | As reported via digital diary (mobile phone application) |
Countries
Netherlands
Outcome results
None listed